Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 3
1948 3
1949 2
1951 34
1952 79
1953 86
1954 97
1955 106
1956 103
1957 82
1958 76
1959 86
1960 73
1961 93
1962 113
1963 220
1964 268
1965 155
1966 196
1967 239
1968 276
1969 262
1970 280
1971 313
1972 338
1973 293
1974 334
1975 275
1976 209
1977 228
1978 214
1979 164
1980 153
1981 107
1982 128
1983 133
1984 118
1985 115
1986 84
1987 99
1988 111
1989 106
1990 157
1991 240
1992 258
1993 242
1994 211
1995 245
1996 270
1997 278
1998 306
1999 264
2000 359
2001 360
2002 462
2003 501
2004 509
2005 607
2006 695
2007 765
2008 780
2009 853
2010 975
2011 1050
2012 1199
2013 1278
2014 1402
2015 1482
2016 1530
2017 1516
2018 1492
2019 1690
2020 1778
2021 356
Text availability
Article attribute
Article type
Publication date

Search Results

28,108 results
Results by year
Filters applied: . Clear all
Page 1
DLBCL Cell of Origin: What Role Should It Play in Care Today?
Rutherford SC, Leonard JP. Rutherford SC, et al. Oncology (Williston Park). 2018 Sep 15;32(9):445-9. Oncology (Williston Park). 2018. PMID: 30248164 Free article. Review.
Diffuse large B-cell lymphoma (DLBCL) is curable in about two-thirds of patients. ...In 2000, gene expression profiling was used to define two principal DLBCL molecular subtypes, germinal center B-cell-like (GCB) and
Diffuse large B-cell lymphoma (DLBCL) is curable in about two-thirds of patients. ...In 2000, gene
Management of diffuse large B-cell lymphoma (DLBCL).
Kubuschok B, Held G, Pfreundschuh M. Kubuschok B, et al. Cancer Treat Res. 2015;165:271-88. doi: 10.1007/978-3-319-13150-4_11. Cancer Treat Res. 2015. PMID: 25655614 Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. ...Assignment of DLBCL according to the gene expression profile into DLBLC originating from a germinal center B cell (GC type) or f
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. ...Assignmen
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ. Li S, et al. Pathology. 2018 Jan;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006. Epub 2017 Nov 20. Pathology. 2018. PMID: 29167021 Review.
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. ...The most popular system divides cases of DLBCL
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma world
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.
Liu Y, Barta SK. Liu Y, et al. Am J Hematol. 2019 May;94(5):604-616. doi: 10.1002/ajh.25460. Am J Hematol. 2019. PMID: 30859597 Free article. Review.
DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes tha …
DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non- …
Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, Shipp MA. Bojarczuk K, et al. Blood. 2019 Jan 3;133(1):70-80. doi: 10.1182/blood-2018-08-872465. Epub 2018 Oct 15. Blood. 2019. PMID: 30322870 Free PMC article.
Inhibition of the B-cell receptor (BCR) signaling pathway is a promising treatment strategy in multiple B-cell malignancies. However, the role of BCR blockade in diffuse large B-cell lymphoma (DLBCL) remains un …
Inhibition of the B-cell receptor (BCR) signaling pathway is a promising treatment strategy in multiple B-cell m …
[CD5-positive DLBCL: molecular basis and treatment strategies].
Miyazaki K. Miyazaki K. Rinsho Ketsueki. 2015 Aug;56(8):1038-44. doi: 10.11406/rinketsu.56.1038. Rinsho Ketsueki. 2015. PMID: 26345564 Japanese.
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) comprises 10% of DLBCL and is one of the immunohistochemical subgroups in the 2008 WHO classification. ...P-glycoprotein, which is associated with multidrug resistance, was po …
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) comprises 10% of DLBCL and is one o …
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. Schmitz R, et al. N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445. N Engl J Med. 2018. PMID: 29641966 Free PMC article.
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gen …
Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH. Swerdlow SH. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):90-9. doi: 10.1182/asheducation-2014.1.90. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696840 Review.
Identification of large B-cell lymphomas that are "extra-aggressive" and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is of great interest. ...Class …
Identification of large B-cell lymphomas that are "extra-aggressive" and may require therapy other than that used for …
Classifying DLBCL Subtypes for Optimal Treatment.
Crombie J. Crombie J. Oncology (Williston Park). 2019 Oct 28;33(10):686504. Oncology (Williston Park). 2019. PMID: 31661151 Free article.
DLBCL is the most common subtype of non-Hodgkin lymphoma, representing about 30% to 40% of cases. ...When pathologists look under the microscope, they can see a diffused proliferation of large neoplastic B cells. These B cells are identified by
DLBCL is the most common subtype of non-Hodgkin lymphoma, representing about 30% to 40% of cases. ...When pathologists look un
28,108 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page